3 Houston innovators to know this week

Who's who

This week's roundup of Houston innovators includes Anouk van Pol of INGU Solutions, Eric Tait of Urban Capital Network, and Chris Howard of Softeq. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from venture capital to energy — recently making headlines in Houston innovation.

Anouk van Pol, co-founder and COO of INGU Solutions

INGU Solutions has established its U.S. office in Houston — and is ready to tap into the city's energy industry with its revolutionary pipeline inspection-as-a-service model. Photo via LinkedIn

After generating some fresh funds from U.S. investors in 2019, Canadian pipeline services company INGU Solutions decided it was time to open a new office somewhere in the country. The startup led by a father-daughter team chose Houston and opened up an office just ahead of the first wave of the COVID-19 pandemic.

“The idea was to be closer to our customers,” Anouk van Pol, COO, tells InnovationMap. “Houston is the oil and gas hub, and just being able to be in [our clients'] offices and be there in person it just helps. I hope at one point COVID passes and that we can make use out of it a bit more.

Despite the challenges of the pandemic, INGU, which uses data analytics and a small sensor to inspect pipes within the energy and water industries, grew 60 percent over the past two years. Click here to read more.

Eric Tait, co-founder at Urban Capital Network

Urban Capital Network have launched a fund-of-funds to allow investors to tap into later-stage startups at a much lower barrier of entry. Photo via urbancapitalnetwork.com

With its new fund of funds, Houston-based Urban Capital Network is allowing its members the chance to invest in venture funds at a much lower barrier of entry. The Horizon Fund II will deploy capital in up to five funds — each with 15 to 30 portfolio companies.

Eric Tait, co-founder at UCN, says they are looking for variety in the funds they invest in and are targeting top-tier, and highly rated VC firms all over the country that UCN's leadership has connections with.

“We’re relatively agnostic in terms of industry,” Tait says. “We do try to have a portfolio allocation that will create a return threshold that is varied.” Click here to read more.

Chris Howard, CEO and founder of Softeq

A Houston software company has announced its new venture fund. Photo courtesy of Softeq

Last week, Houston-based Softeq Development Corporation, a global full-stack development company, launched The Softeq Venture Fund, a $40 million venture fund to invest in seed and series A startup rounds. According to a news release, more than half the fund will be deployed to power the Softeq Venture Studio, Softeq's recently launched accelerator program.

“For generations, the state of Texas has been home to world-renowned tech companies who have greatly contributed to our regional success. As a local entrepreneur, advisor, and angel investor, it’s been my dream for many years to create a venture fund benefiting startups," says Christopher A. Howard, founder and CEO of Softeq, in the release. "I am proud to increase our support of the state’s early-stage tech community. Our investment fund is designed to attract tech visionaries from both inside and outside the state and grow innovative concepts in Houston." Click here to read more.

Urban Capital Network have launched a fund-of-funds to allow investors to tap into later-stage startups at a much lower barrier of entry. Images via urbancapitalnetwork.com

Houston group launches equitable fund of funds to increase impact at a lower barrier of entry

more access to funding

Early stage investing has always been a tried and true way for investors to get in on the ground floor of a tech company for a smaller financial commitment — but it's risky. Urban Capital Network has created an alternative.

UCN was founded to democratize investment opportunities and help investors of color find investment opportunities all while cutting their teeth as novice investors. Lenny Saizan, co-founder of UCN, says that its Horizon Fund II allows for UCN investors to get involved in venture-backed companies at a much lower price tag.

Saizan explains that UCN members are in that lower tier of accredited investors who don't necessarily have $250,000 or $1 million to invest in a fund — but they have $15,000 to $25,000 to invest.

"We allow more people to participate in venture funds or venture-backed opportunities," Saizan tells InnovationMap. "Instead of going into one deal at a very early stage, you’re getting in a later stage where the deal is more de-risked and you have a better chance of returns."

As members start to see returns on these premium investment opportunities, Saizan says, UCN encourages their investors to look at earlier stage within their own communities.

“We recognized that there was still an issue with minority founders getting funded as well,” Saizan says of UCN's mission as a whole. “We thought the best approach would be to create wealth and income within the communities that those founders would be reaching out to.”

Horizon Fund II will deploy capital in up to five funds — each with 15 to 30 portfolio companies. The first two investment opportunities have already been secured: Pegasus Tech Ventures's Pre-IPO Fund and Mercury Fund V, a Houston VC firm. In two years, UCN has seen five exits across its six funds. It's the group's second fund of funds — the first was an investment in Mercury Fund IV.

Eric Tait, co-founder at UCN, says they are looking for variety in the funds they invest in and are targeting top-tier, and highly rated VC firms all over the country that UCN's leadership has connections with.

“We’re relatively agnostic in terms of industry,” Tait says. “We do try to have a portfolio allocation that will create a return threshold that is varied.”

Typically, Tait explains, investing in a VC fund won't garner returns for seven to 10 years. However, UCN specifically targeted Pegasus's Pre-IPO Fund because ROI is expected between years two and four.

Tait says one of the things of focus for UCN this year is to grow the network's reach.

“A big goal for us is to tap into more institutional investors — like family offices, and things of that nature,” Tait says. “What we’ve realized is what we’ve been able to do for individual investors has been locked down, and we can do the same thing on a smaller scale for institutional dollars who are interested in these opportunities but don’t want to put in $1 million.”

Saizan says his team is also looking to give members a tech upgrade when it comes to accessing information and deals on UCN's platform. Additionally, he wants to focus on strengthening the group's network of VCs and how UCN interacts with them. He says firms reach out with interest all the time, and he wants to streamline that process using technology.

“We really want to formalize our network,” Saizan says. “We’re bringing diverse deal flow, diverse investors, diverse talent, and a diverse perspective. So, a lot of times VCs tap us when they are looking for an opportunity — or maybe they have an opportunity and want to know what we think.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings